Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,510,735
  • Shares Outstanding, K 46,772
  • Annual Sales, $ 0 K
  • Annual Income, $ -80,870 K
  • 60-Month Beta 2.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.21
Trade REPL with:

Options Overview Details

View History
  • Implied Volatility 85.53%
  • Historical Volatility 41.90%
  • IV Percentile 74%
  • IV Rank 62.51%
  • IV High 104.48% on 05/19/21
  • IV Low 53.94% on 08/25/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.55
  • Number of Estimates 6
  • High Estimate -0.50
  • Low Estimate -0.61
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.83 +0.49%
on 09/28/21
33.97 -8.80%
on 09/17/21
-0.48 (-1.53%)
since 08/27/21
3-Month
27.66 +12.00%
on 08/26/21
40.22 -22.97%
on 06/29/21
-8.39 (-21.31%)
since 06/28/21
52-Week
21.51 +44.03%
on 09/29/20
54.85 -43.52%
on 11/19/20
+9.40 (+43.56%)
since 09/28/20

Most Recent Stories

More News
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with...

REPL : 30.78 (-4.71%)
Replimune to Present at Two Upcoming Investor Conferences

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(R) platform, today announced that members from the Replimune management...

REPL : 30.78 (-4.71%)
Replimune to Present at the William Blair Biotech Focus Conference 2021

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(R) platform, today announced that Robert Coffin, Ph.D., President and...

REPL : 30.78 (-4.71%)
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs

REPL : 30.78 (-4.71%)
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma

REPL : 30.78 (-4.71%)
Replimune Appoints Tanya Lewis as Chief Development Operations Officer

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(R) platform, today announced the strengthening of its executive team...

KPTI : 6.24 (-4.29%)
REPL : 30.78 (-4.71%)
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo(R) (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo(R) (nivolumab) in anti-PD1 Failed Melanoma

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(R) platform, today announced a clinical development update for CERPASS,...

REPL : 30.78 (-4.71%)
Replimune to Host Virtual Investor Event on June 3, 2021

Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(R) platform, today announced it will host an investor event to present...

REPL : 30.78 (-4.71%)
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, today announced the strengthening of its executive team...

DNA : 12.65 (-4.74%)
REPL : 30.78 (-4.71%)
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2

REPL : 30.78 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 34.04
2nd Resistance Point 33.41
1st Resistance Point 32.86
Last Price 30.78
1st Support Level 31.68
2nd Support Level 31.05
3rd Support Level 30.50

See More

52-Week High 54.85
Fibonacci 61.8% 42.11
Fibonacci 50% 38.18
Fibonacci 38.2% 34.25
Last Price 30.78
52-Week Low 21.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar